Original Article
Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo

Chun-Te Chen1*, Yi-Chun Chen1*, Hirohito Yamaguchi1, Mien-Chie Hung1,2,3

1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; 2Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan; 3Department of Biotechnology, Asia University, Taichung 413, Taiwan. *Equal contributors.

Received April 28, 2015; Accepted June 19, 2015; Epub November 15, 2015; Published December 1, 2015

Abstract: Drug repurposing is a therapeutic strategy that applies drugs to treat different diseases based on new therapeutic function. Carglumic acid (Carbaglu; Orphan Europe) is an orphan drug approved by the FDA for hyperammonemia. Administration of carglumic acid for treatment of hyperammonemia has few side effects and has been used for 10 years to effectively treat hyperammonemia symptoms of both adult and pediatric patients. Here, we tested the potential of carglumic acid to be repurposed as an anticancer agent and showed that carglumic acid promotes apoptosis and inhibits cancer cell growth in a wide variety of human cancers, including pancreatic ductal adenocarcinoma, triple-negative breast cancer (TNBC), hepatoma, and lung cancer. Our data from in vivo models indicates that orally taking 10% of the carglumic acid dose currently used for the treatment of hyperammonemia is effective to suppress the growth of pancreatic ductal adenocarcinoma and TNBC. If given intravenously, only 5% of the carglumic acid dose is needed to be effective against TNBC. These findings suggest that carglumic acid may serve as a safe and effective therapeutic to treat both TNBC and pancreatic cancer.

Keywords: Carbaglu, carglumic acid, urea cycle disorder, drug repurposing

Introduction

The practice of drug repurposing, which is a strategy of using a drug to treat a condition other than that for which the drug was originally approved, has become more common in current decade [1]. Drug repurposing is also known as drug repositioning, repurposing, and therapeutic switching which have proven to be successful approaches for repurposing existing drugs for new indications. For example, thalidomide, an immunomodulatory drug, was successfully repurposed to treat cancer, and mitofosine, originally approved as an anticancer drug, was repurposed to treat visceral leishmaniasis [2]. One of the main advantages of drug repurposing is that the drugs of interest have already been approved by the U.S. Food and Drug Administration and are known to be safe. In addition, repurposed drugs can bypass the early drug development stages, thereby reducing the time and cost of research and development [3].

In this study, we tested the potential of carglumic acid (Carbaglu; Orphan Europe), an orphan drug that was approved in 2010 by the U.S. Food and Drug Administration for treatment of hyperammonemia, to be repurposed as an anticancer agent [4-6]. Hyperammonemia is a disorder of the urea cycle, a biochemical reaction that eliminates ammonia in humans and other mammals by converting it into urea. Urea cycle disorder is caused by genetic deficiencies in urea cycle enzymes or liver function failure, resulting in excess ammonia in the human body. Ammonia is highly toxic and can cause serious harm to the human body, especially to the brain [7, 8]. The first enzyme in the urea cycle to process excess ammonia is carbamoyl phosphate synthetase 1 (CPS1). CPS1 can be activated only by N-acetylglutamate (NAG), which is synthesized from glutamate and acetyl coenzyme A by NAG synthase (NAGS). Inactivation of NAGS reduces cellular NAG levels, which causes CPS1 inactivation and hyperammonemia [9,
Carglumic acid possesses anti-cancer activity

Carglumic acid, a functional analogue of NAG and a CPS1 activator, is used to treat acute and chronic hyperammonemia associated with NAGS deficiency.

In seeking to assess the potential of carglumic acid to be repurposed as an anticancer agent, we were guided in part by the example of sodium phenylbutyrate (PB). PB facilitates an alternative pathway for excretion of excess ammonia and has been used to treat urea cycle disorder for over a decade [11, 12]. PB functions as a histone deacetylase inhibitor [13-15], which is distinct from carglumic acid. However, both PB and carglumic acid are able to reduce ammonemia. PB has been shown to induce apoptosis and cell cycle arrest and associate with anticancer activity [13]. Although it is not yet known whether the anticancer activity of PB is due to urea cycle activation, we asked whether carglumic acid might also possess anti-cancer activity.

To this end, we tested the activity of carglumic acid against 19 human cancer cell lines, including human pancreatic ductal adenocarcinoma (PDAC), human triple-negative breast cancer, human hepatoma, and human non-small cell lung carcinoma cell lines. We also tested the activity of carglumic acid in orthotopic mouse models of human pancreatic and breast cancer. This work demonstrates a novel anticancer function of carglumic acid, with less toxicity than that of chemotherapeutic agents. Carglumic acid therefore may represent an effective alternative for cancer treatment.

Materials and methods

Drugs

Carglumic acid and paclitaxel were purchased from Sigma-Aldrich (St. Louis, MO, USA). Gemcitabine was obtained from the Department of Pharmacy of The University of Texas MD Anderson Cancer Center (Houston, TX, USA).

Cell lines

The human pancreatic adenocarcinoma cell lines Capan1 and AsPc1/luc; murine pancreatic adenocarcinoma cell line Pan02/luc; human triple-negative breast cancer cell lines MDA-MB-231, MDA-MB-468, and HS578T; murine triple-negative breast cancer cell line 4T1; human hepatoma cell lines Hu7, HepG2, Hep3B, HA22T/VGH, HAS9T/VGH, PCL/PRF/5, TONG, SK-Hep-1, and Mahlavu; and human lung cancer cell lines PC9 and H1299 were maintained in Dulbecco modified Eagle/F12 medium supplemented with 10% fetal bovine serum. Human papillomavirus type 16 E6E7-immortalized human pancreatic ductal epithelial cells (HPDE-E6E7 cells) were maintained in keratinocyte serum-free medium. The breast epithelial cell line MCF-12A was maintained in Ham's F12/Dulbecco modified Eagle medium supplemented with 5% horse serum, penicillin (50 U ml⁻¹), streptomycin (50 U ml⁻¹), epidermal growth factor (20 ng ml⁻¹), insulin (10 μg ml⁻¹), cholera toxin (1 ng ml⁻¹), and hydrocortisone. AsPc1/luc and Pan02/luc cells with stable luciferase expression were maintained in a culture medium containing G418. Cell lines were validated by short tandem repeat DNA fingerprinting using the AmpFISTR Identifier PCR Amplification Kit (Applied Biosystems; catalogue no. 4322288) according to the manufacturer's instructions.

Cell viability assay

Cell viability was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay [16]. In brief, various cancer cell lines were seeded (1 x 10⁴ cells/well) in a 96-well plate and treated with different doses of carglumic acid, paclitaxel, or gemcitabine. After 48 h, 50 μl of MTT solution per well (stock solution concentration 5 mg/ml; Sigma-Aldrich) was added to each well, and the cells were incubated for 2 h more, followed by addition of 100 μl of dimethyl sulfoxide (Sigma-Aldrich) to each well. Absorbance at 570 nm was measured immediately using a multiwell scanner (Labsystems, Helsinki, Finland).

Cell cycle assay

After cells were treated with different doses of carglumic acid for 48 h, they were detached by trypsin-EDTA and washed with phosphate-buffered saline. The cells were suspended in 0.5 ml of phosphate-buffered saline and fixed with 4.5 ml of 70% ethanol. After removal of ethanol and a wash with phosphate-buffered saline, the cells were mixed with 500 μl of 0.1 mg/ml propidium iodide (P4170, Sigma) and 500 μl of 2 mg/kg RNase (R5125, Sigma-Aldrich) staining.
Carglumic acid possesses anti-cancer activity

![Graphs showing cell viability of cancer cells](image)

**Figure 1.** Effect of carglumic acid on viability of pancreatic cancer cells. Human pancreatic cancer cell lines were treated with the indicated doses of carglumic acid. Cell viability (absorbance at 570 nm) was determined by MTT assay. The viability of untreated cells (control) was assigned a value of 100%. Each sample was tested in triplicate.

![Graphs showing cell viability of cancer cells](image)

**Figure 2.** Effect of carglumic acid on viability of triple-negative breast cancer cells. Breast cancer cell lines were treated with the indicated doses of carglumic acid. Cell viability (absorbance at 570 nm) was determined by MTT assay. The viability of untreated cells (control) was assigned a value of 100%. Each sample was tested in triplicate.

solution at room temperature in the dark for 45 min. DNA content profiles were evaluated with a BD FACSCanto II cell analyzer (BD Immunocytometry Systems; BD Biosciences, San Jose, CA, USA).

**Caspase activity assay**

Caspase activity was measured by using a fluorimetric caspase-3 assay kit (CASP3F, Sigma-Aldrich). In brief, cells that were treated with
Carglumic acid possesses anti-cancer activity

Figure 3. Effect of carglumic acid on viability of hepatoma cancer cells. Human hepatoma cancer cell lines were treated with the indicated doses of carglumic acid. Cell viability (absorbance at 570 nm) was determined by MTT assay. The viability of untreated cells (control) was assigned a value of 100%. Each sample was tested in triplicate.

carglumic acid or that were left untreated were lysed in a lysis buffer, and 50 μg of protein lysate was incubated with Ac-DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin) substrate in the assay buffer for 1 h. The resultant fluorescence signals were read by using a fluorometer (excitation 360 nm, emission 460 nm), and the results were tabulated as fold changes relative to the untreated control cells.

Mouse studies

For orthotopic cancer models, AsPC1/luc human pancreatic cancer cells (1 x 10⁶) were injected into the pancreas of nude mice or MDA-MB-231 human triple-negative breast cancer cells (3 x 10⁶) were injected into the mammary fat pad of nude mice [17]. Carglumic acid was administered to mice 5 days after tumor inoculation in the pancreatic cancer model and 7 days after tumor inoculation in the triple-negative breast cancer model. Tumor-bearing mice received acarglumic acid dose of 120 mg/kg orally every day for 10 days, 60 mg/kg orally three times per week for 2 weeks, or 60 mg/kg intravenously three times per week for 2 weeks. A 120-mg/kg/day dose of carglumic acid in mice is equivalent to a 10-mg/kg/day dose in humans, which is 10% of the maintenance therapy dose of carglumic acid for hyperammonemia patients [18]. Tumor volume was determined by measuring luciferase signals using the IVIS invivo imaging system (Xenogen, Alameda, CA, USA) in the pancreatic cancer model. All animal procedures were conducted in accordance with the regulations of the Department of Veterinary Medicine and
Carglumic acid possesses anti-cancer activity

![Graphs showing cell viability of different cancer cell lines](image)

**Figure 4.** Effect of carglumic acid on viability of lung cancer cells. Human non-small cell lung cancer cell lines were treated with the indicated doses of carglumic acid. Cell viability (absorbance at 570 nm) was determined by MTT assay. The viability of untreated cells (control) was assigned a value of 100%. Each sample was tested in triplicate.

![Bar graphs showing sub-G1 phase and caspase-3 activity](image)

**Figure 5.** Carglumic acid induces apoptosis in cancer cells. AsPC1 and MDA-MB-231 cells were treated with the indicated doses of carglumic acid. Treated and untreated (0 mM) cancer cells were stained with propidium iodide to evaluate cell apoptosis. A. Percent sub-G1-phase cells among AsPC1 cells. B. Percent sub-G1-phase cells among MDA-MB-231 cells. C. Caspase-3 activity in AsPC1 cells. Each sample was tested in triplicate.

Surgery at The University of Texas MD Anderson Cancer Center. The protocol (protocol no. 190511133) was reviewed and approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.

**Results**

**Carglumic acid inhibits cancer cell growth**

To test the therapeutic effect of carglumic acid in human cancers, we first determined the cytotoxic effect of carglumic acid in various cancer cell lines. Carglumic acid suppressed cell viability in the pancreatic ductal adenocarcinoma cell lines (Figure 1), triple-negative breast cancer cell lines (Figure 2), hepatocarcinoma cell lines (Figure 3), and human non-small cell lung carcinoma cell lines (Figure 4) in a dose-dependent manner. The 50% inhibitory concentration (IC50) of carglumic acid against those cell lines was between 5 and 7.5 mM, suggesting that carglumic acid potently suppressed cancer cell growth.

**Carglumic acid inhibits cancer cell proliferation and induces apoptosis**

To further validate the antiproliferation activity of carglumic acid in cancer cells, we performed fluorescence-activated cell sorting analysis.
Carglumic acid possesses anti-cancer activity

Figure 5. Carglumic acid-treated and untreated cancer cells were stained with propidium iodide to determine DNA contents in AsPC1 and MDA-MB-231. In addition to revealing cell cycle status, this assay can be used to assess cell death by analysis of DNA fragmentation [19]. The results showed that carglumic acid did not induce complete cell cycle arrest. Instead, we observed more sub-G1 cells among carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells, indicating that cell death occurred in response to carglumic acid. Sub-G1 cells accounted for 1.6% and 26.3% of untreated and treated AsPC1 cells, respectively (Figure 5A), and for 1.8% and 12.8% of untreated and treated MDA-MB-231 cells, respectively (Figure 5B). In order to further determine whether cancer cells under go cell death through apoptosis after carglumic acid treatment, we measured caspase activity in AsPC1 cells treated with carglumic acid. The results showed that caspase-3 activity increased in a dose-dependent manner (Figure 5C). Together, these data suggest that carglumic acid inhibits cancer cell proliferation by inducing apoptosis.

Carglumic acid is a relatively safer anti-cancer agent than chemotherapeutic drugs

To determine whether carglumic acid cytotoxicity is specific to cancer cells, we determined the cytotoxic effect of carglumic acid in various human normal epithelial cells, including normal pancreatic ductal epithelial cells and normal breast epithelial cells. We also compared the cytotoxic effects of carglumic acid and chemotherapeutic drugs between normal epithelial cell lines and cancer cell lines. The chemotherapeutic drugs we tested were paclitaxel and...
Carglumic acid possesses anti-cancer activity

gemcitabine, which are commonly used to treat breast cancer and pancreatic cancer, respectively [20, 21]. The human pancreatic ductal epithelial cell line HPDE-E6E7 and human pancreatic ductal adenocarcinoma cell line AsPC1 were treated with different concentrations of carglumic acid or gemcitabine. The normal breast epithelial cell line MCF-12A and triple-negative breast cancer cell line MDA-MB-231 were treated with different concentrations of carglumic acid or paclitaxel. In AsPC1 and HPDE-E6E7 cells, the IC₅₀s of carglumic acid were 5 mM and over 10 mM, respectively (Figure 6A), and the IC₅₀s of gemcitabine were over 100 μM and 1 μM, respectively (Figure 6B). In MDA-MB-231 and MCF-12A cells, the IC₅₀s of carglumic acid were 5 mM and 6 mM, respectively (Figure 6C), and the IC₅₀s of paclitaxel were over 100 μM and 0.39 μM, respectively (Figure 6D). Thus, cancer cells are much more resistant to chemotherapeutics, e.g., gemcitabine and paclitaxel, than normal cells. Carglumic acid does not have this drawback as an anti-cancer drug as it inhibited proliferation of cancer cells slightly more effectively than that of normal cells. Therefore, carglumic acid is expected to be relatively safer than chemotherapeutic drugs.

Carglumic acid inhibits tumor growth in vivo

To test the therapeutic effect of carglumic acid in vivo, we established an AsPC1/luc orthotopic pancreatic cancer model and an MDA-MB-231 orthotopic triple-negative breast cancer model. Tumor-bearing mice were treated with 60 mg/kg carglumic acid either orally or intravenously three times per week for 2 weeks. Arrows represent carglumic acid dose administrations. *P < 0.05; n = 5.

Figure 7. Therapeutic efficacy of carglumic acid in orthotopic models of human pancreatic adenocarcinoma and triple-negative breast cancer. A. AsPC1/luc cells were inoculated into the pancreas in mice to generate human pancreatic adenocarcinoma. Starting at 5 days after cancer cell inoculation, mice were orally administered 120 mg/kg carglumic acid every day for 10 days. B. MDA-MB-231 cells were inoculated into mouse mammary glands to generate human triple-negative breast cancer. Starting at 7 days after tumor inoculation, mice were orally administered 120 mg/kg carglumic acid every day for 10 days. C. The oral (PO) and intravenous (IV) routes of carglumic acid administration were compared in terms of tumor volume reduction in the orthotopic triple-negative breast cancer model. Tumor-bearing mice were treated with 60 mg/kg carglumic acid either orally or intravenously three times per week for 2 weeks. Arrows represent carglumic acid dose administrations. *P < 0.05; n = 5.
Carglumic acid possesses anti-cancer activity

Orthotopic triple-negative breast cancer model [16, 22]. Tumor-bearing mice were given 120 mg/kg carglumic acid orally once a day for 10 days (1200 mg/kg/mouse total). We monitored tumor growth as described in Materials and Methods. The results showed that carglumic acid, but not the vehicle control, markedly inhibited tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by carglumic acid on day 21 was 80% (Figure 7A, P < 0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by carglumic acid on day 20 was 82% (Figure 7B, P < 0.01). These results indicate that carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer.

We also compared the anticancer effect of carglumic acid administered orally with the anticancer effect of carglumic acid administered intravenously in the orthotopic triple-negative breast cancer model. Tumor-bearing mice were given 60 mg/kg carglumic acid by either oral administration or intravenous injection. The drug was given to mice three times per week for 2 weeks (360 mg/kg/mouse total). On day 20, mean tumor growth inhibition in orally and intravenously treated mice was 55% and 93%, respectively, relative to untreated mice (Figure 7C, P < 0.01). These results suggest that the dose of carglumic acid required to produce a > 80% reduction in triple-negative breast tumor volume by intravenous injection is one-third the dose required to produce the same effect by oral administration.

Discussion

Drug repurposing offers the advantages of time and cost savings stemming from the fact that the drug being repurposed has already passed toxicity and safety testing and therefore has a reduced chance of failure [23]. In this study, we found that carglumic acid, which is conventionally used to treat hyperammonemia, has anticancer activity. We found that carglumic acid induced apoptosis in various cancer cells in vitro. Our results indicated that carglumic acid inhibits proliferation of human pancreatic cancer, triple-negative breast cancer, hepatoma, and lung cancer cells by inducing apoptosis. Importantly, carglumic acid is a relatively safer anti-cancer agent than gemcitabine or paclitaxel, which is in agreement with the fact that no serious safety issue has been identified for the use of carglumic acid in treatment of hyperammonemia. Carglumic acid also demonstrated potent antitumor activity in vivo in orthotopic mouse models of human pancreatic and breast cancer. Together, these findings demonstrate a novel anticancer function of carglumic acid, with less toxicity than that of chemotherapeutic agents. Carglumic acid therefore represents an effective alternative for cancer treatment.

Carglumic acid suppresses tumor growth and promotes cell apoptosis by activating caspase 3. The two major mechanisms of caspase cascade-associated apoptosis are an extrinsic signaling pathway involving the tumor necrosis factor receptor gene superfamily to conduct intracellular signaling pathways and an intrinsic mitochondrial pathway initiates non-receptor-mediated intracellular signals [24]. Further investigation is required to distinguish the two mechanisms and to identify other potential mechanisms, such as dysregulation of cancer cell metabolism (see below), which may be associated with carglumic acid-mediated anticancer activities.

For the potential use of carglumic acid to treat cancer, intravenous injection offers a greater tumor volume reduction over than oral administration. Intravenous injection delivers the drug directly to the blood stream, by passing liver metabolism and facilitating essentially 100% bioavailability. Intravenous injection also avoids the side effects associated with irritation of the gastrointestinal tract by orally administered carglumic acid, such as vomiting, abdominal pain, and diarrhea [25, 26].

Since as an analog of NAG, carglumic acid activates CPS1, the first enzyme and rate-limiting step of the urea cycle, hyperactivation of the urea cycle may result in dysregulation of cancer cell metabolism. Recently, it has been shown that cancer cells and normal cells have different metabolic profiles, and these differences may render cancer cells more vulnerable [27]. The mechanism by which the activation of the urea cycle induces apoptosis in cancer cells warrants further investigation. In addition to playing a role in urea cycle regulation, CPS1 may play an important role in suppressing cancer cell growth by inducing cell apoptosis. Alternatively, activation of urea cycle by itself
may induce anti-cancer activities via dysregulation of cancer cell metabolism.

Acknowledgements
We thank Arthur Gelmis from Scientific Publications at MD Anderson for editing the manuscript. This work was supported in part by National Institutes of Health (CA109311, CA099031, and Cancer Center Support Grant CA16672), the Center for Biological Pathways and the ShRNA and ORFeome Core Facility of MD Anderson Cancer Center, National Breast Cancer Foundation, Inc., the Breast Cancer Research Foundation, the Patell Memorial Breast Cancer Endowment Fund, The University of Texas MD Anderson Cancer Center Sister Institution Network Fund (M.-C. Hung), Ministry of Science and Technology, International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 104-2911-I-002-302), and Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TDU-B-212-124-002).

Disclosure of conflict of interest
M.-C. Hung, C.-T. Chen, and Y.-C. Chen are inventors on patents for carglumic acid as an anticancer drug.

Address correspondence to: Mien-Chie Hung, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 108, Houston, TX 77030, USA. Tel: 713-792-3668; Fax: 713-794-3270; E-mail: mhung@mdanderson.org

References
Carglumic acid possesses anti-cancer activity


